It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

<sup>1</sup>**Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and** 

# <sup>2</sup>**adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)**

- 3 Germán Áñez, $^1$  Alice McGarry, $^1$ Wayne Woo, $^1$  Karen L. Kotloff, $^2$  Cynthia L. Gay, $^3$  Mingzhu Zhu, $^1$
- 4 Shane Cloney-Clark,<sup>1</sup> Joy Nelson,<sup>1</sup> Haoua Dunbar,<sup>1</sup> Miranda R. Cai,<sup>1</sup> Iksung Cho,<sup>1</sup> Zhaohui
- 5 Cai,<sup>1</sup> Raj Kalkeri,<sup>1</sup> Joyce S. Plested,<sup>1</sup> Nita Patel,<sup>1</sup> Katherine Smith,<sup>1</sup> Anthony M. Marchese,<sup>1</sup>
- 6 Gregory M. Glenn,<sup>1</sup> Raburn M. Mallory,<sup>1</sup> Lisa M. Dunkle,<sup>1</sup> for the 2019CoVn-301 Study
- 7 Investigators
- 8 <sup>1</sup>Novavax, Inc., Gaithersburg, Maryland, USA
- <sup>2</sup>Center for Vaccine Development and Global Health, University of Maryland School of Medicine,
- 10 Baltimore, Maryland, USA
- <sup>3</sup> Institute for Global Health and Infectious Diseases, University of North Carolina School of
- 12 Medicine, Chapel Hill, North Carolina, USA
- 13

# <sup>14</sup>**Correspondence:**

- 15 Lisa M. Dunkle, MD<br>16 700 Quince Orchard
- 16 700 Quince Orchard Road., Gaithersburg, MD 20878<br>17 Idunkle@novavax.com
- 17 ldunkle@novavax.com<br>18 ORCID: 0009-0000-885
- <sup>18</sup>ORCID: 0009-0000-8856-3341
- 19

# <sup>20</sup>**Abbreviations**

- <sup>21</sup>AE, adverse event; AESI, adverse event of special interest; ELISA, enzyme-linked
- 22 immunosorbent assay; hACE2-RBI, human angiotensin-converting enzyme-2 receptor binding
- 23 inhibition; GMEU, geometric mean ELISA unit; GMFR, geometric mean fold rise; GMT,
- 24 geometric mean titer; LLOQ, lower limit of quantification; MAAE, medically attended adverse
- 25 event; nAb, neutralizing antibody; NP, nucleoprotein; PIMMC, potentially immune-mediated
- <sup>26</sup>medical condition; PP-IMM, per-protocol immunogenicity; rS, recombinant Spike; SAE, serious
- 27 adverse event; SCR, seroconversion rate; TEAE, treatment-emergent adverse event.
- 28
- <sup>29</sup>**Article type:** Original Research Article
- <sup>30</sup>**Abstract word count:** 298/300
- <sup>31</sup>**Word count:** 3767/5000
- <sup>32</sup>**Figures/tables (10 limit):** 4**/**<sup>1</sup>
- <sup>33</sup>**References:** 28/50
- 34

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### <sup>35</sup>**ABSTRACT** [word count: 298/300]

#### <sup>36</sup>**Background**

- 37 NVX-CoV2373, a recombinant SARS-CoV-2 spike (rS) protein vaccine with Matrix-M™ adjuvant,
- 38 has been authorized for use in adults and adolescents. PREVENT-19
- <sup>39</sup>(NCT04611802/2019nCoV-301), a pivotal phase 3, randomized, placebo-controlled trial
- <sup>40</sup>demonstrated robust efficacy of a primary, 2-dose series of NVX-CoV2373 against COVID-19.

#### <sup>41</sup>**Methods**

- <sup>42</sup>Protocol expansions to PREVENT-19 included enrollment of adolescents (aged 12 to <18
- 43 years) and administration of  $3<sup>rd</sup>$  and  $4<sup>th</sup>$  doses of NVX-CoV2373 to adults and adolescents.
- 44 Participants randomized 2:1 received NVX-CoV2373 or placebo 21 days apart;  $3^{\text{rd}}$  and  $4^{\text{th}}$  doses
- <sup>45</sup>were administered ≥6 months after the preceding dose. Secondary and additional assessments
- 46 included post–3 $^{rd}$  and 4<sup>th</sup>-dose immune responses (neutralizing antibody [nAb], anti-rS  $\log$ ,
- 47 human angiotensin-converting enzyme-2–receptor binding inhibition [hACE2-RBI]) and
- 48 response durability (post–3<sup>rd</sup> dose) to ancestral virus; cross-reactivity to Omicron subvariants;
- 49 safety; and reactogenicity.

#### <sup>50</sup>**Results**

- 51 Immune responses were observed against ancestral virus after two doses of NVX-CoV2373 but
- 52 not after placebo. In both adults and adolescents, additional doses of NVX-CoV2373 increased
- 53 nAb titers, anti-rS IgG levels, and hACE2-RBI; durable responses were recorded 8 months post
- $54$   $3<sup>rd</sup>$  dose. nAb responses post  $3<sup>rd</sup>$  dose were noninferior to those post primary series. Cross-
- 55 reactivity to BA.5 and BQ.1.1 variants was also observed, with anti-rS IgG levels post 3<sup>rd</sup> or 4<sup>th</sup>
- 56 dose exceeding previously reported correlates of protection. Additional doses of NVX-CoV2373
- 57 were well tolerated, with no new safety signals.

#### <sup>58</sup>**Conclusions**

- 59 NVX-CoV2373 elicited robust and durable humoral immune responses to ancestral SARS-
- 60 CoV-2 as a 3<sup>rd</sup> and 4<sup>th</sup> dose after the primary series in adults and adolescents. Cross-reactivity
- 61 to relevant variants provides insight into potential protection against antigenically related, but
- 62 shifted, viral strains. Additional doses of NVX-CoV2373 were well tolerated with no new safety
- <sup>63</sup>signals. These results support the utility of this vaccine platform and continued updates, based
- 64 on currently circulating strains, to help effectively combat SARS-CoV-2 infection.
- <sup>65</sup>**Keywords (3–8):** COVID-19, vaccine, durability, reactogenicity, booster, adolescent

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.07.24316930;](https://doi.org/10.1101/2024.11.07.24316930) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY-NC-ND 4.0 International license.

- **Highlights** (3–5 bullets; 85 characters, including spaces, per bullet)
- NVX-CoV2373 elicits robust and durable humoral immune responses to SARS-CoV-2  $\bullet$  3<sup>rd</sup> and 4<sup>th</sup> subsequent homologous doses are immunogenic and well tolerated • NVX-CoV2373 was cross-reactive to variants circulating at the time of this study
- 

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.07.24316930;](https://doi.org/10.1101/2024.11.07.24316930) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

## **1. Introduction**



It is made available under a CC-BY-NC-ND 4.0 International license.

 $3<sup>rd</sup>$  dose and subsequent 4<sup>th</sup> dose. This report describes immunogenicity and safety results from 98 adults and adolescents enrolled in PREVENT-19, including outcomes from participants who 99 received additional doses of NVX-CoV2373. Immunogenicity against the ancestral strain and 100 cross-reactivity against viral variants predominant at the time of this report are included.

#### <sup>101</sup>**2. Methods**

#### <sup>102</sup>*2.1. Study design*

103 Enrollment criteria for adult<sup>8</sup> and adolescent (aged 12 to <18 years)<sup>10</sup> participants were 104 described previously. Participants were randomized 2:1 to receive two intramuscular injections 105 of either NVX-CoV2373 or placebo 21 days apart (Figure S1). After accrual of safety data to 106 support Emergency Use Authorization, participants could opt in for the blinded crossover and 107 receive alternate treatment from their original randomization group. Adult participants in study 108 follow-up for ≥6 months (≥5 months for adolescents) after receipt of the NVX-CoV2373 primary 109 series were eligible for a 3<sup>rd</sup> dose (open label); a 4<sup>th</sup> dose was offered at select sites ≥6 months 110 later.

<sup>111</sup>*2.2. Objectives* 

112 Results of primary efficacy, initial safety, and some secondary objectives post primary series in 113 adults and adolescents have been reported previously.<sup>8,10</sup> Final adult safety outcomes, as well 114 as updated immunogenicity and safety analyses post–primary series dosing and outcomes and 115 after  $3^{rd}$  and  $4^{th}$  doses in adults and adolescent participants are reported here. Secondary 116 immunogenicity objectives were neutralizing antibody (nAb) titers, serum IgG levels, and human <sup>117</sup>angiotensin-converting enzyme-2 (hACE2) receptor-binding inhibition (RBI) before and 14 days 118 after (day 35) the NVX-CoV2373 primary series. The 14-day timepoint for the primary series 119 was used in this study based on timing in pivotal COVID-19 vaccine trials in the height of the 120 pandemic.<sup>8,11</sup> Immune responses 28 days after the 3<sup>rd</sup> and 4<sup>th</sup> doses and comparison of these to 121 the primary series responses were assessed.

It is made available under a CC-BY-NC-ND 4.0 International license.

122 Safety assessment included collection of solicited local and systemic reactogenicity for 7 123 days after each study dose and incidence and severity of unsolicited adverse events (AEs) for 124 28 days after each study dose. Overall safety included frequency and severity of treatment-125 related medically attended AEs (MAAEs), AEs of special interest (AESI), serious AEs (SAEs), 126 and death due to any cause throughout study follow-up.

<sup>127</sup>*2.3. Procedures* 

128 Participants received NVX-CoV2373 (5 μg SARS-CoV-2 rS protein and 50 μg Matrix-M

129 adjuvant) via a 0.5-mL intramuscular injection. Blood samples for measurement of serum

130 antibody responses were collected on day 0 (before the 1<sup>st</sup> dose), day 35 (14 days following the

131  $2<sup>nd</sup>$  dose), and before and 28 days after the 3<sup>rd</sup> and 4<sup>th</sup> doses. Blood samples and nasal swabs

132 were obtained from participants before the primary series,  $3<sup>rd</sup>$ , and  $4<sup>th</sup>$  doses to determine

133 serologic and virologic status (SARS-CoV-2 anti-nucleoprotein [NP] serum antibodies [Elecsys®

134 Anti-SARS-CoV-2 assay; University of Washington, Seattle, WA, USA]; SARS-CoV-2 RT-PCR

<sup>135</sup>[Abbott Real Time Quantitative SARS-CoV-2 assay; University of Washington, Seattle, WA,

136 USA]).

137 Reactogenicity (solicited AEs) data were documented by participants via an eDiary for 7 138 days after dosing. Unsolicited treatment-emergent AEs (TEAEs) were collected through 28 days 139 after each study dose; treatment-related MAAEs, AESI, SAEs, and death (any cause) were 140 documented by study investigators through end of study.

<sup>141</sup>*2.4. Assessments* 

142 Serum was analyzed with validated assays for: nAbs specific to ancestral SARS-CoV-2 (via a 143 microneutralization inhibitory concentration of 50% [MN<sub>50</sub>]; 360biolabs, Melbourne, Australia),<sup>12</sup> 144 anti-rS IgG antibody levels via enzyme-linked immunosorbent assay (ELISA) as geometric 145 mean ELISA units (GMEUs),<sup>13</sup> and hACE2 RBI antibodies to rS protein<sup>14</sup> (both assays; Novavax

It is made available under a CC-BY-NC-ND 4.0 International license. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.11.07.24316930;](https://doi.org/10.1101/2024.11.07.24316930) this version posted November 11, 2024. The copyright holder for this

146 Clinical Immunology, Gaithersburg, MD, USA). Fit-for-purpose assays were used for anti-rS IgG

147 and nAbs against variant strains (ie, BA.5, BQ.1.1).<sup>15</sup>

148 Solicited AEs were summarized by local/systemic symptom and maximum severity.

149 Unsolicited AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA)

150 version 25.0. AEs were categorized by severity and relationship to the study vaccine.

<sup>151</sup>*2.5. Statistical analyses* 

152 The per-protocol immunogenicity (PP-IMM) analysis sets for each dose included participants

<sup>153</sup>with both a baseline (pre-dose) and ≥1 post-dose sample and no exclusionary protocol

154 violations. Participants with RT-PCR–positive nasal swabs and/or anti-NP seropositivity for

155 SARS-CoV-2 from baseline to day 35 and/or through 28 days after the 3<sup>rd</sup> or 4<sup>th</sup> study dose

156 were excluded from PP-IMM analyses. All statistical analyses were performed using  $SAS^{\circledast}$ 

157 version 9.4 or higher (SAS Institute, Cary, NC).

158 Geometric means were defined as the antilog of the mean of the log-transformed values. 159 Geometric mean fold rise (GMFR) was defined as the ratio of post-dose to pre-dose geometric 160 mean values within a study group. Data were summarized by trial vaccine group using 95% CI, <sup>161</sup>calculated based on the *t*-distribution of the log-transformed values for geometric means or 162 GMFR, then back-transformed to the original scale for presentation. For ratio calculations, 163 concentration values below the lower limit of quantification (LLOQ) were replaced by 0.5  $\times$ <sup>164</sup>LLOQ. Seroconversion rate (SCR) was defined as a percentage of participants with a ≥4-fold 165 higher antibody level post versus pre-dose. The SCR 95% CIs were calculated using the exact 166 Clopper–Pearson method.

167 Noninferiority of the  $3<sup>rd</sup>$ -dose response to that following the primary series was assessed 168 by comparing the nAb titers 28 days after the  $3<sup>rd</sup>$  dose with the response obtained 14 days after 169 the primary series. To establish noninferiority, the following criteria were to be met: lower bound 170 of two-sided 95% CI for the ratio of GMTs (GMT $_{\text{third}}$ /GMT $_{\text{primary}}$ ) >1.0 and lower bound of the two-

It is made available under a CC-BY-NC-ND 4.0 International license.

171 sided 95% CI for the difference of SCR (SCR<sub>third</sub>−SCR<sub>primary</sub>) >−10%. The 95% CI for SCR 172 difference was calculated using the Tango method. Serum samples from randomly selected 173 adult and adolescent PP-IMM subsets, who received all four doses, were used to assess 174 immune responses against ancestral SARS-CoV-2 and variants at the specified time points. 175 The safety analysis sets included all participants who received ≥1 primary series study 176 dose and were analyzed according to study material received; participants in the  $3<sup>rd</sup>$ - and  $4<sup>th</sup>$ -177 dose safety sets must have received these respective additional vaccinations. Reactogenicity 178 data are reported for participants in the safety analysis set with ≥1 eDiary entry for the 179 associated dose. Safety data were summarized descriptively, and no statistical tests were 180 performed. Unsolicited AEs were reported by number and percentage, with corresponding exact 181 95% CI using the Clopper–Pearson method. <sup>182</sup>*2.6. Ethical oversight*  183 This study was performed in accordance with the International Conference on Harmonization <sup>184</sup>Good Clinical Practice guidelines and overseen by the NIAID DSMB. The protocol, 185 amendments, and overall oversight were provided by institutional review boards, research 186 ethics committees, and the National Institute of Allergy and Infectious Disease (NIAID) Data 187 Safety and Monitoring Board (DSMB), according to local regulations. Written informed consent 188 was received from all participants before enrollment. <sup>189</sup>**3. Results** 

#### <sup>190</sup>*3.1. Study populations*

191 Adult participants (N=29,943; screened from 27 December 2020 to 18 February 2021) were

- 192 randomized to receive NVX-CoV2373 (N=19,961) or placebo (N=9982); 713 and 337
- 193 participants were included in the respective PP-IMM analysis sets (Figure 1A). After crossover,
- 194 226 and 160 adult participants were in the 3<sup>rd</sup>- and 4<sup>th</sup>-dose sets, respectively (**Figure 1B**). Of

It is made available under a CC-BY-NC-ND 4.0 International license.

195 2247 adolescent participants, 1491 and 756, respectively, were randomized to receive NVX-

196 CoV2373 and placebo (PP-IMM sets: 1126 and 537); there were 122 and 27 adolescent

197 participants analyzed for immunogenicity after the  $3<sup>rd</sup>$  dose and  $4<sup>th</sup>$  dose, respectively

<sup>198</sup>(**Figure 1**).

199 Demographic characteristics were comparable among treatment arms within adult PP-<sup>200</sup>IMM (**Table 1**) and safety (**Table S1**) sets, other than a higher proportion of 18- to 64-year-old 201 participants in the adult PP-IMM set who received a  $3<sup>rd</sup>$  dose, compared to other doses; 202 characteristics were also comparable among treatment arms within the adolescent sets. Adult 203 and adolescent participants received  $3<sup>rd</sup>$  or 4<sup>th</sup> doses after a median of 6–12 months following 204 the preceding dose (**Figure S1**).

<sup>205</sup>*3.2. Immunological responses to the ancestral strain in adults and adolescents* 

206 hAb ( $MN_{50}$ ) GMTs to the ancestral strain in adults rose from 11 to 1083 in the NVX-<sup>207</sup>CoV2373 group (GMFR, 103 [95% CI, 92.4–115.6]) from day 0 to day 35 (**Figure 2A**). No 208 antibody response was detected in placebo-recipients from a baseline GMT of 10. Day 35 SCRs 209 were 94% with NVX-CoV2373 versus 2% with placebo. Additional doses of NVX-CoV2373 210 increased titers from pre-dose to 28 days post dose for both the  $3<sup>rd</sup>$  and  $4<sup>th</sup>$  doses, resulting in 211 nAb titers greater than those observed 14 days post primary series. Similar response trends 212 were observed across doses of NVX-CoV2373 in the adolescent population (**Figure 2B**). 213 Noninferiority was achieved for the nAb response 28 days after the  $3<sup>rd</sup>$  dose compared to 14 214 days after the primary series (GMTR and SCR difference) in both the adult and adolescent 215 populations (**Figure 2C**). 216 In adults, anti-rS IgG GMEUs rose from 119 to 49,384 in the NVX-CoV2373 group <sup>217</sup>(GMFR, 414 [368.8–464.2]) from day 0 to 35 versus no apparent change from day 0 (GMEU, <sup>218</sup>108) in the placebo group (GMFR, 1.2 [95% CI, 1.1–1.3]) (**Figure S2A**). GMEUs also 219 substantially increased from pre-dose to 28 days post  $3<sup>rd</sup>$  and  $4<sup>th</sup>$  doses. Adolescent participants 220 had low baseline GMEUs on day 0 and a robust increase on day 35 post active vaccination

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

<sup>221</sup>(**Figure S2B**). Titers remained high with subsequent doses. hACE2 RBI GMTs followed a 222 similar pattern as nAb and serum IgG responses in both adults (**Figure S3A**) and adolescents <sup>223</sup>(**Figure S3B**). Immunological responses after the primary series among participants regardless 224 of baseline serostatus were comparable to those in the baseline seronegative PP-IMM sets 225 across each of the assays (**Figure S4**). 226 **Durability of immunogenic response was assessed 4- and 8-months post 3<sup>rd</sup> dose in** 227 subsets of the PP-IMM populations. Importantly, nAb, anti-rS IgG, and hACE2 RBI responses to 228 the ancestral strain were preserved at levels comparable to those recorded 28 days after the 3 $^{\text{rd}}$ 229 dose (Figure S5). Titers remained elevated from baseline and there were only minor declines in 230 GMFR and SCRs through 8 months post  $3<sup>rd</sup>$  dose. <sup>231</sup>*3.3. Immunological responses to the ancestral strain in adult age subgroups* 

232 Baseline nAb, serum IgG, and hACE2 RBI values were similar (within each assessment) <sup>233</sup>among participants aged 18 to <65 years and ≥65 years in both treatment groups (**Table S2**). 234 Fourteen days after the primary series, the nAb titers in the NVX-CoV2373 group were ~1.4-fold 235 higher in participants aged 18 to  $\leq$  65 years (123.8 [107.1–143.1]) compared with those aged 236 ≥65 years (86.1 [72.6–102.1]). Increases in serum IgG and hACE2 RBI titers on day 35 followed 237 a similar trend. SCRs from day 0 to day 35 for each of the response measures were comparable 238 among the adult age groups. Immune responses in adults who received a  $3<sup>rd</sup>$  and/or  $4<sup>th</sup>$  dose of 239 NVX-CoV2373 were similar in younger and older adults (Table S3).

<sup>240</sup>*3.4. Cross-reactivity of NVX-CoV2373 against Omicron subvariants* 

241 hAb responses ( $ID_{50}$ ) to BA.5 and BQ.1.1 were assessed in a PP-IMM subset of adult 242 participants who received all four study doses of NVX-CoV2373. Fourteen days after the 243 primary series, responses that cross-reacted with variant strains were  $\sim$ 100-fold lower than 244 those against the ancestral strain; however, activity increased against each variant with 245 subsequent doses of NVX-CoV2373 (Figure 3A).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



<sup>254</sup>*3.5. Reactogenicity* 

255 Overall, solicited AEs were predominantly mild to moderate in severity and self-limited. Events 256 occurred at a somewhat higher frequency after the  $3<sup>rd</sup>$  and  $4<sup>th</sup>$  doses compared with the first two <sup>257</sup>doses (**Figure 4A; Table S4**). Solicited AEs were reported most frequently within 2 days after 258 vaccination and lasted a median 1–3 days; there were a limited number of AEs lasting >7 days 259 post injection (**Table S5**). Frequencies of solicited local AEs across doses trended similarly in 260 both the adult and adolescent study populations; following each dose, pain and tenderness 261 were the most common (>10%). Any solicited systemic AEs also occurred with similar frequency 262 among the adult and adolescent study populations (Figure 4B; Table S4). Fatigue, headache, 263 malaise, and muscle pain were the most common (>40% for any dose) solicited systemic AEs 264 reported.

<sup>265</sup>*3.6. Unsolicited AEs* 

266 Through 28 days after the primary series, unsolicited AEs occurred at similar frequencies within 267 the adult and adolescent populations in the NVX-CoV2373 (12.1% and 15.8%, respectively) and 268 placebo (11.6% and 16.0%) groups (**Table S6**). Frequency of unsolicited AEs decreased with 269 the  $3^{\text{rd}}$  and 4th doses of NVX-CoV2373 in both adults and adolescents. After the  $4^{\text{th}}$  dose, no 270 adults and one (0.5%) adolescent participant had a vaccine-related AE (urticaria). Overall, there 271 was minimal occurrence of vaccine-related or severe AEs, as well as MAAEs, SAEs, and

272 PIMMCs. During primary series follow-up, six adult participants discontinued the study for an 273 unsolicited AE considered related to study vaccination. After unblinding, it was determined these 274 were four and two participants in the active vaccine and placebo groups, respectively. At the 275 data cutoff date, there were no unsolicited AEs leading to discontinuation in adolescent 276 participants. No deaths during the study were considered related to vaccination, and there were 277 no deaths in the adolescent population.

#### <sup>278</sup>**4. Discussion**

279 These results expand on previous reports of the PREVENT-19 trial<sup>8,10</sup> and support phase 3 280 data<sup>17</sup> that demonstrated the safety and efficacy of two primary doses of NVX-CoV2373 in 281 adults and adolescents. Immunological responses to ancestral SARS-CoV-2 were markedly 282 increased 14 days after two primary doses of NVX-CoV2373 in participants serologically 283 negative for SARS-CoV-2 NP. Responses were durable, with continued robust humoral 284 responses after a  $3^{\text{rd}}$  dose of NVX-CoV2373 and modest increases after a  $4^{\text{th}}$  dose. Over the full 285 period of the study, antibody titers were sustained in the range associated with a high degree of 286 protective efficacy.<sup>16</sup> Overall, NVX-CoV2373 was immunogenic in both younger and older adults 287 and adolescents and was well tolerated.

288 In both adults and adolescents, immunological response to a  $3<sup>rd</sup>$  dose of NVX-CoV2373 289 was noninferior to that observed 14 days after the primary series. A median of 8 months after 290 the  $3^{\text{rd}}$  dose, a 4<sup>th</sup> dose of NVX-CoV2373 resulted in elevated nAb titers comparable to those 291 post  $3^{rd}$  dose, and  $>4$ -fold higher than those observed 28-days post primary series. These 292 positive  $3^{\text{rd}}$ -dose responses are in line with those previously reported from a phase 2 trial.<sup>18</sup> nAb 293 titers before the  $3^{\text{rd}}$  and  $4^{\text{th}}$  doses were higher than those reported on Day 0, indicating response 294 durability. Notably, there was some decline in titers, indicative of waning immunity; however, this 295 can be expected as it would align with previously reported waning vaccine efficacy (to Delta 296 variants) >120 days post vaccination.<sup>19</sup> Although mRNA COVID-19 vaccines have generally

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

297 reported higher absolute post-vaccination IgG levels and neutralization titers, other studies have 298 demonstrated significantly better persistence of response with NVX-CoV2373, with a slower 299 decline in immune responses.<sup>20</sup> These data support the rationale for periodic reimmunization to 300 help combat breakthrough infection in vaccinated individuals, especially with the frequent 301 emergence of new variant strains. 302 **Overall, AEs were mild to moderate and reactogenicity was generally transient.** <sup>303</sup>Incidence and severity of local and systemic reactogenicity moderately increased following the 304  $-2^{nd}$  dose and remained relatively consistent after both the 3<sup>rd</sup> dose and 4<sup>th</sup> dose. These findings 305 align with early studies during the pandemic where a COVID-19 vaccine primary series (ie, 306 mRNA, adenoviral vector, and protein-based) was observed to generally elicit higher 307 frequencies of reactogenic symptoms following the  $2^{nd}$  dose compared to the 1<sup>st</sup> dose.<sup>11,21,22</sup> 308 Side effects from COVID-19 vaccines have been identified as a driving force of vaccine 309 hesitancy;<sup>23,24</sup> therefore, a key observation from this study may be that additional doses of NVX-310 CoV2373 in adult and adolescent populations did not further increase reactogenic symptom 311 frequency. Here, unsolicited AE frequency after the primary series was comparable in the NVX- $312$  CoV2373 and placebo groups and incidence appeared to plateau after the  $4<sup>th</sup>$  dose, which is 313 consistent with data from a phase 2 study conducted in Australia and the US.<sup>21</sup> Notably, the 314 solicited and unsolicited AE outcomes after repeat dosing with NVX-CoV2373 are reassuring for

315 future recommendations of additional doses of the Novavax COVID-19 vaccine, based on

316 updated formulations that are expected due to continued SARS-CoV-2 strain circulation and

317 evolution.

<sup>318</sup>A tolerable safety profile, immunogenicity, and protection from infection in older adults is 319 of great interest for COVID-19 vaccines due to the higher risk of severe disease complications  $320$  in those aged ≥65 years.<sup>25</sup> No safety concerns were raised, and high and similar immune 321 responses were observed across age groups; however, as expected, titers were lower in the 322 older versus younger adult population, and titers were higher for the adolescent versus adult

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

323 populations. Notably, in both age groups, responses were within the range demonstrated to 324 provide protective efficacy.<sup>16</sup> This is an important consideration, as real-world evidence 325 indicates that vaccine side effects are a key factor in selection of a specific vaccine formulation 326 when efficacy among the options is comparable.<sup>26</sup> Overall, the decision for use of a protein- or <sup>327</sup>mRNA-based vaccine formulation should consider patient characteristics/comorbidities and 328 individual preference (eg, vaccine hesitancy due to side effects), as well as immunogenicity. <sup>329</sup>Cross-protective humoral immune responses were observed against Omicron variants 330 BA.5 and BQ.1.1. Over time, SARS-CoV-2 lineages have evolved, attaining increased fitness 331 and immune evasion capabilities, compared to the ancestral strain and early Omicron variants. <sup>332</sup>For example, additional mutations in the viral spike protein may promote improved replication in 333 respiratory cells, decreased affinity for ACE2, and antibody resistance.<sup>27</sup> A 3<sup>rd</sup> dose of 334 NVX-CoV2373 elicited a robust serum IgG response to BA.1 with an SCR comparable to that 335 observed after the primary series. These data are in line with those from a phase 2 study of a 336 smaller South African population, where elevated titers against BA.1 and BA.4/5 were observed 337 after  $3^{rd}$  and  $4^{th}$  doses of NVX-CoV2373.<sup>28</sup> These immunogenicity results provide supportive 338 evidence for this protein-based vaccine platform's capacity to elicit broadly cross-reactive nAb 339 titers against antigenically distant SARS-CoV-2 variant strains. 340 This study was conducted during the early years of what has become a continuously

341 evolving epidemiology of SARS-CoV-2. At study initiation, virtually all participants were 342 infection-naive, and ancestral virus, as well as some early antigenically related variants, were 343 circulating. During the second year, more antigenically divergent variants emerged (eg, BA.1, <sup>344</sup>BA.5, and BQ.1.1), reducing immunity among individuals vaccinated with authorized prototype 345 vaccines. This led to recommendations for "booster" doses of the prototype vaccine, followed by 346 updated vaccine formulations that targeted newer variants. For the 2023–2024 season, 347 vaccines based on the XBB.1.5 variant became available.<sup>2,3</sup> JN.1, followed by strains within that <sup>348</sup>lineage (ie, KP.2 and KP.3), then became the dominant strains, and two mRNA-based vaccines

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.07.24316930;](https://doi.org/10.1101/2024.11.07.24316930) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

349 and the Novavax COVID-19 vaccine were authorized/approved as updated COVID-19 vaccines 350 for the 2024–2025 season.<sup>7</sup> In non-clinical models, the updated Novavax COVID-19 vaccine <sup>351</sup>(NVX-CoV2705 [JN.1]) generated broad cross-neutralizing responses against JN.1-lineage 352 subvariants, including KP.2 and KP.3. $^{29}$  The continued authorizations, preclinical data, and 353 assessments with convalescent serum samples suggest consistency for immunogenicity and 354 effectiveness of updated Novavax COVID-19 vaccines with this platform.

<sup>355</sup>Immune responses described here demonstrate cross-reactivity of the prototype vaccine 356 with genetic variants that had deviated from ancestral SARS-CoV-2. It can be expected that 357 immunogenicity of prototype vaccines would decline as new strains emerge and antigenic 358 distance grows. For example, based on genomic composition, early Omicron strains (eg, BA.1, 359 BA.5, and BQ.1) may be considered one antigenically related "family", followed by a larger shift to XBB-related strains that are more antigenically distinct from ancestral SARS-CoV-2.<sup>30</sup> 361 Notably, within these 'antigenic families' of variants, cross-reactivity to updated vaccines may be 362 more likely.

363 A separate analysis of data from PREVENT-19 reported that nAb titers provide a 364 correlate of protection for NVX-CoV2373 against ancestral virus,<sup>16</sup> and a more recent analysis<sup>19</sup> 365 confirmed antibody levels to the immune-evading Delta variant that support protective efficacy. 366 This vaccine platform also demonstrated cross-reactivity in the 2019nCoV-313/NCT05975060 367 study investigating an updated version of NVX-CoV2373 directed to XBB.1.5 (NVX-CoV2601), 368 *[in press]*, which was authorized for use in 2023–2024.<sup>2,3</sup> In that study, nAb responses to JN.1 369 and KP.2 were observed in previously vaccinated participants (≥3 doses of an mRNA-based 370 COVID-19 vaccine) who received one dose of NVX-CoV2601. Cross-reactivity against SARS-371 CoV-2 variants by vaccines generated using this platform may be related to unique platform 372 attributes, such as the saponin-based Matrix-M adjuvant and/or greater accessibility to highly 373 conserved spike protein epitopes due to the truncated glycans of glycoproteins produced in the 374 baculovirus expression vector system.<sup>31</sup> Matrix-M adjuvant likely broadens epitope recognition<sup>32</sup>

medRxiv preprint doi: [https://doi.org/10.1101/2024.11.07.24316930;](https://doi.org/10.1101/2024.11.07.24316930) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a CC-BY-NC-ND 4.0 International license.

- 375 and elicits a Th1-dominant immune response capable of improving humoral immune
- 376 responses<sup>33</sup>. Despite the continued evolution of SARS-CoV-2, the ancestral vaccine and strain
- 377 responses analyzed in this study allow for the interpretation of cross-reactivity specific to this
- 378 vaccine platform, which can provide insight into potential performance of updated vaccine
- 379 formulations against antigenically distant future-drifted strains.

#### <sup>380</sup>**5. Conclusions**

- <sup>381</sup>In conclusion, NVX-CoV2373 elicited robust and durable humoral immune responses to
- 382 SARS-CoV-2, as well as cross-protective responses to key variants. Doses of NVX-CoV2373
- 383 beyond the primary series induced spike-specific antibodies, with an acceptable reactogenicity
- 384 profile. These results support continuing updates to this vaccine platform based on currently
- 385 circulating strains to help effectively combat SARS-CoV-2 infection.

386

387

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### <sup>389</sup>**Acknowledgments**

<sup>390</sup>We especially thank each of the study participants who volunteered for this study, as well as the 391  $2019nCoV-301$  Study Group members.<sup>8,10</sup> We acknowledge the funders (BARDA and 392 NIAID/NIH), the members of the NIAID Data and Safety Monitoring Board (DSMB), community 393 leadership groups throughout the country who assisted with community engagement and 394 recruitment, unnamed colleagues at each of the sites who generously contributed to the trials in 395 many ways, and all unnamed colleagues at Novavax, Inc, who worked tirelessly and gave 396 unlimited efforts to the development, testing, and support of this trial. Medical writing support 397 was provided by Kelly Cameron, PhD, CMPP, Kelly M. Fahrbach, PhD, CMPP, with editorial 398 support from Ebenezer M. Awuah-Yeboah, BS, all of Ashfield MedComms (New York, USA), an 399 Inizio company, supported by Novavax, Inc.

#### <sup>400</sup>**Appendix A**: Supplementary data

401 Supplementary study results.

<sup>402</sup>**Funding:** This work was supported by Novavax, Inc.; the Office of the Assistant Secretary for <sup>403</sup>Preparedness and Response, Biomedical Advanced Research and Development Authority <sup>404</sup>(BARDA; contract Operation Warp Speed: Novavax Project Agreement number 1 under Medical 405 CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium base agreement 406 no. 2020-530; Department of Defense no. W911QY20C0077); and the National Institute of 407 Allergy and Infectious Diseases (NIAID), National Institutes of Health. The NIAID provides grant <sup>408</sup>funding to the HIV Vaccine Trials Network (HVTN) Leadership and Operations Center (UM1 <sup>409</sup>AI68614), the HVTN Statistics and Data Management Center (UM1 AI68635), the HVTN 410 Laboratory Center (UM1 AI68618), the HIV Prevention Trials Network Leadership and 411 Operations Center (UM1 AI68619), the AIDS Clinical Trials Group Leadership and Operations 412 Center (UM1 AI68636), and the Infectious Diseases Clinical Research Consortium leadership 413 group (UM1 AI148684).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

<sup>414</sup>**Data Statement:** Study details can be found at https://clinicaltrials.gov/study/NCT04611802.

415 Data that support the findings of this study are available in supplementary material and from the

416 corresponding author upon reasonable request.

## <sup>417</sup>**Declaration of Competing Interest**

418 Karen L. Kotloff reports financial support was provided by Novavax, Inc. and the National

119 Institute of Allergy and Infectious Diseases. Cynthia L. Gay reports financial support was

- 420 provided by National Institute of Allergy and Infectious Diseases. Alice McGarry, Wayne Woo,
- 421 Mingzhu Zhu, Shane Cloney-Clark, Joy Nelson, Haoua Dunbar, Miranda R. Cai, Iksung Cho,

<sup>422</sup>Zhaohui Cai, Raj Kalkeri, Joyce S. Plested, Nita Patel, Katherine Smith, Anthony M. Marchese,

423 and Raburn M. Mallory report a relationship with Novavax, Inc. that includes: employment and

<sup>424</sup>equity or stocks. German Anez reports a relationship with Novavax, Inc that includes:

425 employment (former) and equity or stocks. Gregory Glenn reports a relationship with Novavax,

426 Inc. that includes: consulting or advisory, employment (former), and equity or stocks. Lisa

427 Dunkle reports a relationship with Novavax, Inc. that includes: consulting or advisory,

428 employment (former), and equity or stocks. Karen L. Kotloff reports a relationship with Novavax,

429 Inc. that includes: funding grants. Medical writing support was funded by Novavax, Inc. If there

430 are other authors, they declare that they have no known competing financial interests or

431 personal relationships that could have appeared to influence the work reported in this paper.

- <sup>432</sup>**Ethics Approval Statement**
- <sup>433</sup>The study was performed in accordance with the International Conference on Harmonization

434 Good Clinical Practice guidelines and overseen by the NIAID Data Safety and Monitoring Board.

<sup>435</sup>**Patient Consent Statement** 

436 All participants provided written informed consent before enrollment.

437

It is made available under a CC-BY-NC-ND 4.0 International license.

# <sup>439</sup>**Author contributions**

- 440 **Germán Áñez**: conceptualization, methodology, formal analysis, investigation, writing original draft<br>441 **preparation, writing reviewing and editin**g
- preparation, writing  $-$  reviewing and editing
- 442 Alice McGarry: formal analysis, investigation, writing reviewing and editing
- 443 Wayne Woo: formal analysis, investigation, writing reviewing and editing
- 444 Karen L. Kotloff: data curation, investigation, writing reviewing and editing; resources
- 445 Cynthia L. Gay: data curation, investigation, writing reviewing and editing; resources
- 446 Mingzhu Zhu: writing reviewing and editing; resources
- 447 Shane Cloney-Clark: formal analysis, writing reviewing and editing
- 448 **Joy Nelson**: writing reviewing and editing; project administration
- 449 Haoua Dunbar: data curation, writing reviewing and editing
- 450 Miranda R. Cai: formal analysis, writing reviewing and editing
- 451 **Iksung Cho**: formal analysis, investigation, writing reviewing and editing, software
- 452 Zhaohui Cai: formal analysis, writing reviewing and editing
- 453 Raj Kalkeri: investigation, writing reviewing and editing
- 454 Joyce S. Plested: formal analysis, writing reviewing and editing
- 455 Nita Patel: resources, writing reviewing and editing
- 456 Katherine Smith: formal analysis, writing reviewing and editing
- 457 Anthony M. Marchese: writing updated draft preparation, writing reviewing and editing
- 458 Gregory M. Glenn: methodology, investigation, writing reviewing and editing
- 459 Raburn M. Mallory: methodology, formal analysis, writing reviewing and editing
- 460 Lisa M. Dunkle: conceptualization, methodology, formal analysis, investigation, writing reviewing and 461 editing, writing original draft preparation editing, writing – original draft preparation

 $\frac{102}{102}$ 

703<br>3

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### <sup>465</sup>**References**

- 466 1.COVID-19 Vaccine Tracker. Novavax: Nuvaxovid<br>467 https://covid19.trackvaccines.org/vaccines/2
	- https://covid19.trackvaccines.org/vaccines/25/. Accessed January 16, 2024.
- 468 2.Food and Drug Administration. Novavax COVID-19 Vaccine, Adjuvanted. Available online 17<br>469 Cotober 2023. https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber 469 Cotober 2023. https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-<br>470 regulated-biologics/novavax-covid-19-vaccine-adjuvanted. Accessed January 31, 2024. <sup>470</sup>regulated-biologics/novavax-covid-19-vaccine-adjuvanted. Accessed January 31, 2024.
- 471 3.European Medicines Agency. Nuvaxovid. COVID-19 Vaccine (recombinant, adjuvanted).<br>472 https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid#ema-inpage-iter 472 https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid#ema-inpage-item-<br>473 product-info. Accessed February 1, 2024. product-info. Accessed February 1, 2024.
- 474 4. World Health Organization. Updated Risk Evaluation of JN.1, 15 April 2024.<br>475 https://www.who.int/docs/default-475 https://www.who.int/docs/default-<br>476 source/coronaviruse/15042024 in <sup>476</sup>source/coronaviruse/15042024\_jn1\_ure.pdf?sfvrsn=8bd19a5c\_7#:~:text=Effectiveness 477 <u>%20of%20the%20XBB.,predicted%20to%20cross%2Drecognize%20BA</u>. Accessed May<br>478 13, 2024.
- 13, 2024.
- 479 5.Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of Updated 2023-2024 (Monovalent<br>480 KBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infectio 480 XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection<br>481 Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults -481 Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults -<br>482 **Audrey Stephen Community Access to Testing Program**, United States, September 2023 482 Increasing Community Access to Testing Program, United States, September 2023-<br>483 January 2024. MMWR Morb Mortal Wkly Rep. 2024;73(4):77-83. <sup>483</sup>January 2024. *MMWR Morb Mortal Wkly Rep.* 2024;73(4):77-83.
- 
- 484 6.U.S. Food and Drug Administration. Updated COVID-19 Vaccines for Use in the United States<br>485 **Beginning in Fall 2024** https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-485 Beginning in Fall 2024 https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-<br>486 vaccines-use-united-states-beginning-fall-2024. Accessed September 13, 2024. vaccines-use-united-states-beginning-fall-2024. Accessed September 13, 2024.
- 487 7.U.S. Food and Drug Administration. COVID-19 Vaccines. https://www.fda.gov/emergency-<br>488 preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines. 488 preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.<br>489 Accessed September 25, 2024. Accessed September 25, 2024.
- 490 8.Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the 491 United States and Mexico. N Engl J Med. 2022:386(6):531-543. <sup>491</sup>United States and Mexico. *N Engl J Med.* 2022;386(6):531-543.
- 492 9.Marchese AM, Zhou X, Kinol J, et al. NVX-CoV2373 vaccine efficacy against hospitalization:<br>493 A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial. 493 A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.<br>494 Vaccine. 2023;41(22):3461-3466. <sup>494</sup>*Vaccine.* 2023;41(22):3461-3466.
- 495 10.Anez G, Dunkle LM, Gay CL, et al. Safety, Immunogenicity, and Efficacy of the NVX-<br>496 CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA 496 CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. *JAMA Netw And Copen.* 2023;6(4):e239135. <sup>497</sup>*Open.* 2023;6(4):e239135.
- 498 11.Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-<br>499 2 Vaccine. N Engl J Med. 2021;384(5):403-416. <sup>499</sup>2 Vaccine. *N Engl J Med.* 2021;384(5):403-416.
- 500 12.Hamilton S, Zhu M, Cloney-Clark S, et al. Validation of a severe acute respiratory syndrome<br>501 coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity. J Viro 501 coronavirus 2 microneutralization assay for evaluation of vaccine immunogenicity. *J Virol* **Methods.** 2024;327:114945. <sup>502</sup>*Methods.* 2024;327:114945.
- 503 13.Zhu M, Cloney-Clark S, Feng SL, et al. A Severe Acute Respiratory Syndrome Coronavirus 2<br>504 **Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine** 504 Anti-Spike Immunoglobulin G Assay: A Robust Method for Evaluation of Vaccine<br>505 **Immunogenicity Using an Established Correlate of Protection**. Microorganisms. 505 Immunogenicity Using an Established Correlate of Protection. *Microorganisms.* **2023;11(7)**. <sup>506</sup>2023;11(7).

- 507 14. Plested JS, Zhu M, Cloney-Clark S, et al. Severe Acute Respiratory Syndrome Coronavirus<br>508 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A 508 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A<br>509 Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation. 509 Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.<br>510 *Microorganisms.* 2023;11(2). <sup>510</sup>*Microorganisms.* 2023;11(2).
- <sup>511</sup>15.Cai Z, Kalkeri R, Zhu M, et al. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 512 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for<br>513 Vaccine Immunogenicity Evaluation. *Microorganisms.* 2024;12(3). <sup>513</sup>Vaccine Immunogenicity Evaluation. *Microorganisms.* 2024;12(3).
- 514 16.Fong Y, Huang Y, Benkeser D, et al. Immune correlates analysis of the PREVENT-19<br>515 **COVID-19 vaccine efficacy clinical trial**. *Nat Commun.* 2023;14(1):331. <sup>515</sup>COVID-19 vaccine efficacy clinical trial. *Nat Commun.* 2023;14(1):331.
- 516 17. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of the NVX-CoV2373<br>517 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled 517 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a<br>518 **Controlled Controlled Trial**. *Clin Infect Dis.* 2023;76(3):398-407. <sup>518</sup>Randomized Controlled Trial. *Clin Infect Dis.* 2023;76(3):398-407.
- 519 18.Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous<br>520 booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a 520 booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a<br>521 secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect D. 521 secondary analysis of a randomised, placebo-controlled, phase 2 trial. *Lancet Infect Dis.* **2022;22(11):1565-1576**. 2022;22(11):1565-1576.
- 523 19.Follmann D, Mateja A, Fay MP, et al. Durability of Protection Against COVID-19 Through the<br>524 Delta Surge for the NVX-CoV2373 Vaccine. Clin Infect Dis. 2024;79(1):78-85. <sup>524</sup>Delta Surge for the NVX-CoV2373 Vaccine. *Clin Infect Dis.* 2024;79(1):78-85.
- 525 20.Liu X, Munro APS, Wright A, et al. Persistence of immune responses after heterologous and<br>526 homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of 526 homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. J Infect. 2023;87(1):18-26. <sup>527</sup>the COV-BOOST trial. *J Infect.* 2023;87(1):18-26.
- 528 21.Alves K, Plested JS, Galbiati S, et al. Immunogenicity and safety of a fourth homologous<br>529 dose of NVX-CoV2373. Vaccine. 2023:41(29):4280-4286. <sup>529</sup>dose of NVX-CoV2373. *Vaccine.* 2023;41(29):4280-4286.
- 530 22.Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-<br>531 19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. <sup>531</sup>19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
- 532 23.Al-Obaydi S, Hennrikus E, Mohammad N, Lehman EB, Thakur A, Al-Shaikhly T. Hesitancy<br>533 and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine 533 and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine<br>534 rollout in a multi-site healthcare system. *PLoS One.* 2022;17(8):e0272691. <sup>534</sup>rollout in a multi-site healthcare system. *PLoS One.* 2022;17(8):e0272691.
- 535 24. Chrissian AA, Oyoyo UE, Patel P, et al. Impact of COVID-19 vaccine-associated side effects<br>536 on health care worker absenteeism and future booster vaccination. Vaccine. 536 on health care worker absenteeism and future booster vaccination. *Vaccine.* **2022**;40(23):3174-3181. <sup>537</sup>2022;40(23):3174-3181.
- 538 25. Centers for Disease Control and Prevention. People With Certain Medical Conditions.<br>539 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-539 https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-<br>540 medical-conditions.html. Accessed January 31, 2024. medical-conditions.html. Accessed January 31, 2024.
- 541 26.Salisbury D, Lazarus JV, Waite N, et al. COVID-19 Vaccine Preferences in General<br>542 Populations in Canada, Germany, the United Kingdom, and the United States: D 542 Populations in Canada, Germany, the United Kingdom, and the United States: Discrete<br>543 Choice Experiment. JMIR Public Health Surveill. 2024;10:e57242. <sup>543</sup>Choice Experiment. *JMIR Public Health Surveill.* 2024;10:e57242.
- 544 27. Planas D, Staropoli I, Michel V, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and<br>545 BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commu 545 BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. *Nat Commun.* **2024:15(1):2254.** <sup>546</sup>2024;15(1):2254.
- 547 28.Bhiman JN, Richardson SI, Lambson BE, et al. Novavax NVX-COV2373 triggers<br>548 eneutralization of Omicron sub-lineages. Sci Rep. 2023;13(1):1222. <sup>548</sup>neutralization of Omicron sub-lineages. *Sci Rep.* 2023;13(1):1222.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 549 29. Walker R. Vaccines and Related Biological Products Advisory Committee. Novavax Data in 550<br>550 Support of 2024-2025 Vaccine Update. June 5, 2024. Available at: 550 Support of 2024-2025 Vaccine Update. June 5, 2024. Available at:<br>551 https://www.fda.gov/media/179143/download. Accessed October 20 https://www.fda.gov/media/179143/download. Accessed October 20, 2024.
- 552 30.Nextstrain.org. Genomic epidemiology of SARS-CoV-2 with subsampling focused globally<br>553 since pandemic start. https://nextstrain.org/ncov/gisaid/global/all-time?m=div. Accesse 553 since pandemic start. https://nextstrain.org/ncov/gisaid/global/all-time?m=div. Accessed<br>554 August 12, 2024. <sup>554</sup>August 12, 2024.
- 555 31. Wolff MW, Murhammer DW, Jarvis DL, Linhardt RJ. Electrophoretic analysis of glycoprotein<br>556 **1980** alveans produced by lepidopteran insect cells infected with an immediate early 556 glycans produced by lepidopteran insect cells infected with an immediate early<br>557 fecombinant baculovirus encoding mammalian beta1,4-galactosyltransferase. 557 recombinant baculovirus encoding mammalian beta1,4-galactosyltransferase. *Glycoconj* 558 *J.* 1999;16(12):753-756. <sup>558</sup>*J.* 1999;16(12):753-756.
- 559 32.Chung KY, Coyle EM, Jani D, et al. ISCOMATRIX adjuvant promotes epitope spreading and<br>560 antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate 560 antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate<br>561 with virus neutralization in humans. Vaccine. 2015;33(32):3953-3962. <sup>561</sup>with virus neutralization in humans. *Vaccine.* 2015;33(32):3953-3962.
- 562 33.Stertman L, Palm AE, Zarnegar B, et al. The Matrix-M adjuvant: A critical component of vaccines for the 21(st) century. Human vaccines & immunotherapeutics. 563 vaccines for the 21(st) century. *Human vaccines & immunotherapeutics.* **2023;19(1):2189885**.
- <sup>564</sup>2023;19(1):2189885.

**Table 1.** Demographic characteristics (PP-IMM analysis sets).



SD, standard deviation. Note: Demographic and clinical characteristics are shown for the total PP-IMM set and were not developed for individual PP-IMM subsets.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

# **Figure legends**

**Figure 1.** CONSORT diagram.

Participant enrollment and disposition for adult and adolescent populations. (A) Primary series and crossover. (B) Dose expansion.

Part of this figure was adapted from Añez G, et al. *JAMA Netw Open*. 2023;6(4):e239135.

\*Other reasons include receipt of another COVID-19 vaccine, noncompliance, investigator decision, incarceration, and pregnancy. <sup>†</sup>Participants could have more than one reason for exclusion. <sup>‡</sup>Participants with an immunogenicity sample after the 3rd dose were a combination of those who received 2 doses of NVX-CoV2373 in the initial series and those who received 2 doses during blinded crossover. <sup>§</sup>Three participants were excluded from the adult 4<sup>th</sup>-dose safety analysis set due to receipt of an external COVID-19 vaccine or an extra dose of NVX-CoV2373; three participants excluded from the adolescent PP-IMM set who received only 3 doses of NVX-CoV2373 are included in the 4<sup>th</sup>-dose safety analysis set.

**Figure 2.** nAb responses against the ancestral strain in PP-IMM analysis sets. A) Adults. B) Adolescents. C) Noninferiority comparison of nAb responses after the primary series and 3rd dose.

Baseline/pre-dose are defined as the last available assessment prior to administration of trial vaccine for the 1st, 3rd, or 4th dose. Post dose is 14 days (Day 35) after the primary series and 28 days after the 3rd or 4th dose. GMFR was calculated based on titer comparison of respective post vaccination and baseline samples for each group. SCR was calculated based on the number of participants with a  $\geq 4$ -fold increase in antibody concentration from baseline divided number of participants with a ≥4-fold increase in antibody concentration from baseline divided<br>by the number of participants with a sample collected at the designated post vaccination time. GMFR and SCR values with 95% CIs are noted. To establish noninferiority, the following criteria were to be met: lower bound (LB) of two-sided 95% CI for the ratio of GMTs (GMTthird/GMTprimary) >1.0; and LB of the two-sided 95% CI for the difference of SCR (GMTthird − GMTprimary) > −10%. Responses are compared 14 days (Day 35) after the primary series and 28 days after the 3rd dose. Criteria boundaries for 95% CI are marked with a dashed vertical line. GMT, geometric mean titer; LB, lower bound; nAb, neutralizing antibody; SCR, seroconversion rate.

**Figure 3.** Immunogenicity in an adult PP-IMM subset against the ancestral strain, BA.5, and BQ.1.1 before and after the primary series,  $3<sup>rd</sup>$  dose, and  $4<sup>th</sup>$  dose.

A) Pseudovirus neutralization assay (n=15 participants for each timepoint and strain). B) Anti-rS IgG responses regardless of baseline SARS-CoV-2 serostatus (n=40 participants for each timepoint and strain, other than for 38 participants for 28 days after the  $4<sup>th</sup>$  dose). C) Anti-rS IgG responses by baseline SARS-CoV-2 serostatus (n=20 participants for each timepoint and strain, other than for 18 participants for 28 days after the  $4<sup>th</sup>$  dose). Fold differences compared with the ancestral strain for each series are shown in brackets. GMFR are comparing GMTs from samples collected on the day of dosing (before vaccination) with samples collected 28 days after that same dose. CoP values in (B) were determined for the ancestral strain based on Day 35 anti-rS IgG levels with protection 56 days later (Fong et al 2022). CoP, correlate of protection; GMFR, geometric mean fold rise; GMT, geometric mean titer; SCR, seroconversion rate.

It is made available under a CC-BY-NC-ND 4.0 International license.

**Figure 4.** Reactogenicity within 7 days of each study dose.

Solicited (A) local and (B) systemic treatment-emergent adverse events were collected in adult (top) and adolescent (bottom) participants in the safety analysis sets with at least one eDiary entry. Note: There are no placebo reactogenicity data beyond the primary series as subsequent doses of placebo were not administered.

#### **A**



# medRxiv preprint doi: https://doi.org/10.1101/2024.11.07.24316930; this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante is the presult of the authory funder medical state to display is the author/funder, she seeked and prepriated by peer redsignation in perception the preprint in perceptive defined by peer redsignation of  $\alpha$  and  $\alpha$  is t medRxx preprint doi: https://doi.org/10.1101/2024. [;](https://doi.org/10.1101/2024.11.07.24316930) 1077. 24316830; #is version posted November 11, 2024. I he dopyright polder for this and



**Adult booster dose amendment** 

**B** 



medRxiv preprint doi: [https://doi.org/10.1101/2024.11.07.24316930;](https://doi.org/10.1101/2024.11.07.24316930) this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

**Figure 2.** Neutralizing antibody responses to the ancestral strain before and after the primary series,  $3<sup>rd</sup>$ , and  $4<sup>th</sup>$  doses (PP-IMM analysis sets).

# **A.** Adults





#### **B.** Adolescents





It is made available under a CC-BY-NC-ND 4.0 International license.

**C.** Noninferiority comparison of nAb responses after the primary series and 3<sup>rd</sup> dose.



**Figure 3.** Immunogenicity in an adult PP-IMM subset against the ancestral strain, BA.5, and BQ.1.1 before and after the primary series,  $3<sup>rd</sup>$  dose, and  $4<sup>th</sup>$  dose.

A) Pseudovirus neutralization assay (n=15 participants for each timepoint and strain).

B) Anti-rS IgG responses regardless of baseline SARS-CoV-2 serostatus (n=40 participants for each timepoint and strain, other than for 38 participants for 28 days after the  $4<sup>th</sup>$  dose).

C) Anti-rS IgG responses by baseline SARS-CoV-2 serostatus (n=20 participants for each timepoint and strain, other than for 18 participants for 28 28 days after the  $4<sup>th</sup>$  dose).

Fold differences compared to the ancestral strain for each series are shown with brackets. GMFR are comparing GMTs from samples collected on on the day of dosing (before vaccination), to samples collected 28 days after that same dose. CoP in (B) were determined for the ancestral strain based on Day 35 anti-rS IgG levels with protection 56 days later (Fong et al 2022). CoP, correlate of protection; GMFR, geometric mean fold rise; GMT, geometric mean titer; SCR, seroconversion rate.





medRxiv preprint doi: https://doi.org/10.1101/2024.11.07.24316930; this version posted November 11, 2024. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante is the presult of the authory funder medical state to display is the author/funder, she seeked and prepriated by peer redsignation in perception the preprint in perceptive defined by peer redsignation of  $\alpha$  and  $\alpha$  is t medRxx preprint doi: https://doi.org/10.1101/2024. [;](https://doi.org/10.1101/2024.11.07.24316930) 1077. 24316830; #is version posted November 11, 2024. I he dopyright polder for this and

**Figure 4.** Proportion of participants with solicited (A) local and (B) systemic TEAEs within 7 days of each dose of NVX-CoV2373.

